Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02963766 · ClinicalTrials.gov registry record · Phase 3
A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 154
- Enrollment target
NCT02963766 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 154 participants.
The verdict
NCT02963766, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 154 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants with type 2 diabetes. The study duration is approximately 60 weeks.
Interventions
- DRUG Placebo
- DRUG Dulaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2016-12-29 |
| Est. Completion | 2022-01-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02963766
The ClinicalTrials.gov registry entry for NCT02963766 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02963766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02963766 about?
NCT02963766 is a clinical study titled "A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes". The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants with type 2 diabetes. The study duration is approximately 60 weeks.
What is the current status of trial NCT02963766?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 154 participants. The study started on 2016-12-29. Estimated completion is 2022-01-12.
What interventions are being tested in trial NCT02963766?
The interventions under investigation include: Placebo (DRUG), Dulaglutide (DRUG).
Who is sponsoring clinical trial NCT02963766?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.